DZ Bank Discount Zert GILD 27.09..../ DE000DJ8N698 /
| 2024-05-17 9:34:22 PM | Chg.-0.260 | Bid9:59:45 PM | Ask- | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 60.940EUR | -0.42% | 61.160 Bid Size: 1,000 |
- Ask Size: - |
Gilead Sciences Inc | - USD | 2024-09-27 | Call |
GlobeNewswire
05-14
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
GlobeNewswire
05-09
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
05-09
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-08
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
05-08
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
04-29
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire
04-19
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire
04-10
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire
04-02
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire
04-01
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire
03-28
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire
03-28
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GlobeNewswire
03-22
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire
03-18
CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire
03-11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
02-29
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
GlobeNewswire
02-29
Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...
GlobeNewswire
02-28
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...
GlobeNewswire
02-27
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
